{"organizations": [], "uuid": "8c9779666a44fb0e221b0e5ae2192dce1522ef0b", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180529.html", "section_title": "Archive News &amp; Video for Tuesday, 29 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/novo-nordisk-diabetes/novo-nordisks-oral-diabetes-drug-beats-jardiance-in-study-idUSL5N1T060X", "country": "US", "domain_rank": 408, "title": "Novo Nordisk's oral diabetes drug beats Jardiance in study", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.863, "site_type": "news", "published": "2018-05-30T00:55:00.000+03:00", "replies_count": 0, "uuid": "8c9779666a44fb0e221b0e5ae2192dce1522ef0b"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/novo-nordisk-diabetes/novo-nordisks-oral-diabetes-drug-beats-jardiance-in-study-idUSL5N1T060X", "ord_in_thread": 0, "title": "Novo Nordisk's oral diabetes drug beats Jardiance in study", "locations": [], "entities": {"persons": [{"name": "jardiance", "sentiment": "negative"}, {"name": "mads krogsgaard thomsen", "sentiment": "none"}, {"name": "mark heinrich", "sentiment": "none"}, {"name": "ben hirschler", "sentiment": "none"}], "locations": [{"name": "london", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "novo nordisk", "sentiment": "negative"}, {"name": "eli lilly", "sentiment": "none"}, {"name": "boehringer ingelheim", "sentiment": "none"}, {"name": "novo", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "LONDON, May 29 (Reuters) - An experimental diabetes pill from Novo Nordisk proved better at lowering blood sugar levels than Eli Lilly and Boehringer Ingelheim’s established Jardiance in a clinical study, the Danish drugmaker said on Tuesday.\nThe success of oral semaglutide in the Phase III trial is a boost for a medicine seen as important for ensuring the group’s long-term growth in a highly competitive diabetes market.\nThe once-daily pill, which Novo hopes to launch in 2020, belongs to a blockbuster class of treatments known as GLP-1s that stimulate insulin production. So far, all have been injections and a pill would offer a step-change in convenience.\nMads Krogsgaard Thomsen, Novo’s chief science officer, said the positive results from the so-called PIONEER 2 trial were “an important milestone” in the clinical development of oral semaglutide.\nReporting by Ben Hirschler Editing by Mark Heinrich\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-30T00:55:00.000+03:00", "crawled": "2018-05-30T21:10:51.022+03:00", "highlightTitle": ""}